Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label comparison of insulin aspart injection versus NovoRapid in type 2 diabetes mellitus
CTR20233626Phase 3Active
- Sponsor
- Kunpeng Bio
- Start
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by Kunpeng Bio. Started Nov 2023; status: active.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20233626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233626.